ASCO
8 czerwca 2022
American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022
Rok
2022
Cel
RVU120 (CDK8/CDK19), daposertib (MEN1703 / SEL24), PIM/FLT3
Zasoby na tej stronie
Pobierz zasoby
- plik pdf
Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: the DIAMOND-01 trial
Pobierz - plik pdf
Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
Pobierz